Michael Martin Breen - Net Worth and Insider Trading

Michael Martin Breen Net Worth

The estimated net worth of Michael Martin Breen is at least $512,990 dollars as of 2024-06-17. Michael Martin Breen is the Director of Prairie Operating Co and owns about 40,064 shares of Prairie Operating Co (PROP) stock worth over $449,117. Michael Martin Breen is also the Executive Chairman/Interim CEO of GT Biopharma Inc and owns about 21,874 shares of GT Biopharma Inc (GTBP) stock worth over $63,872. Details can be seen in Michael Martin Breen's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the assumption that Michael Martin Breen has not made any transactions after 2023-05-03 and currently still holds the listed stock(s).

Transaction Summary of Michael Martin Breen

To

Michael Martin Breen Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Michael Martin Breen owns 2 companies in total, including GT Biopharma Inc (GTBP) , and Prairie Operating Co (PROP) .

Click here to see the complete history of Michael Martin Breen’s form 4 insider trades.

Insider Ownership Summary of Michael Martin Breen

Ticker Comapny Transaction Date Type of Owner
GTBP GT Biopharma Inc 2023-04-11 director & Exec. Chair. and Interim CEO
PROP Prairie Operating Co 2023-05-03 director

Michael Martin Breen Latest Holdings Summary

Michael Martin Breen currently owns a total of 2 stocks. Among these stocks, Michael Martin Breen owns 40,064 shares of Prairie Operating Co (PROP) as of May 3, 2023, with a value of $449,117 and a weighting of 87.55%. Michael Martin Breen also owns 21,874 shares of GT Biopharma Inc (GTBP) as of April 11, 2023, with a value of $63,872 and a weighting of 12.45%.

Latest Holdings of Michael Martin Breen

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
PROP Prairie Operating Co 2023-05-03 40,064 11.21 449,117
GTBP GT Biopharma Inc 2023-04-11 21,874 2.92 63,872

Holding Weightings of Michael Martin Breen


Michael Martin Breen Form 4 Trading Tracker

According to the SEC Form 4 filings, Michael Martin Breen has made a total of 1 transactions in Prairie Operating Co (PROP) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Prairie Operating Co is the acquisition of 32,064 shares on May 3, 2023, which cost Michael Martin Breen around $100,772.

According to the SEC Form 4 filings, Michael Martin Breen has made a total of 1 transactions in GT Biopharma Inc (GTBP) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in GT Biopharma Inc is the acquisition of 1,667 shares on April 11, 2023, which cost Michael Martin Breen around $25,000.

Insider Trading History of Michael Martin Breen

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Michael Martin Breen Trading Performance

GuruFocus tracks the stock performance after each of Michael Martin Breen's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Michael Martin Breen is 31.82%. GuruFocus also compares Michael Martin Breen's trading performance to market benchmark return within the same time period. The performance of stocks bought by Michael Martin Breen within 3 months outperforms 1 times out of 2 transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Michael Martin Breen's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Michael Martin Breen

Average Return

LIMIT
Average return per transaction

Outperforming Transactions

LIMIT
1 out of 2 outperforming transactions.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) -24.08 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) -26.69 LIMIT LIMIT LIMIT LIMIT LIMIT

Michael Martin Breen Ownership Network

Ownership Network List of Michael Martin Breen

No Data

Ownership Network Relation of Michael Martin Breen

Insider Network Chart

Michael Martin Breen Owned Company Details

What does GT Biopharma Inc do?

Who are the key executives at GT Biopharma Inc?

Michael Martin Breen is the director & Exec. Chair. and Interim CEO of GT Biopharma Inc. Other key executives at GT Biopharma Inc include CFO & Secretary Manu Ohri , Pres. of R&D & CMO Gregory Berk , and Acting Chief Financial Officer Gavin Choy .

GT Biopharma Inc (GTBP) Insider Trades Summary

Over the past 18 months, Michael Martin Breen made 1 insider transaction in GT Biopharma Inc (GTBP) with a net purchase of 50,000. Other recent insider transactions involving GT Biopharma Inc (GTBP) include a net purchase of 50,000 shares made by Manu Ohri ,

In summary, during the past 3 months, insiders sold 0 shares of GT Biopharma Inc (GTBP) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of GT Biopharma Inc (GTBP) were sold and 3,333 shares were bought by its insiders, resulting in a net purchase of 3,333 shares.

GT Biopharma Inc (GTBP)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

GT Biopharma Inc Insider Transactions

No Available Data

Michael Martin Breen Mailing Address

Above is the net worth, insider trading, and ownership report for Michael Martin Breen. You might contact Michael Martin Breen via mailing address: Lowsley House 133 Headley Road, Liphook X0 Gu30 7pu.

Discussions on Michael Martin Breen

No discussions yet.